Pharmaceuticals Europe

Europe HPV Vaccines Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe HPV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Gender, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.66 Bn Placeholder estimate
Estimate 2025 $1.77 Bn 16% of the global market
Projected 2034 $3.09 Bn 74.8% Adds $1.32 Bn over 9 forecast years
CAGR 2025–2034 6.4% Faster than 45% of 180 Pharmaceuticals markets here
Key players 5
  • Europe is 15.98% of the global market.
  • Among regions, the largest is North America at $6.25 Bn.
  • Fastest growing: Africa at 9.6% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.32 Bn total, 2026–2034

Year-by-year market size, 2024–2034
HPV Vaccines Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.66 Bn — —
2025 (base) $1.77 Bn +$106.5 Mn —
2026 (forecast) $1.88 Bn +$113.3 Mn +6.4%
2027 (forecast) $2.00 Bn +$120.6 Mn +13.2%
2028 (forecast) $2.13 Bn +$128.3 Mn +20.5%
2029 (forecast) $2.27 Bn +$136.5 Mn +28.2%
2030 (forecast) $2.41 Bn +$145.2 Mn +36.4%
2031 (forecast) $2.57 Bn +$154.5 Mn +45.1%
2032 (forecast) $2.73 Bn +$164.4 Mn +54.4%
2033 (forecast) $2.91 Bn +$174.9 Mn +64.3%
2034 (forecast) $3.09 Bn +$186.1 Mn +74.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe HPV Vaccines Market Analysis at a glance
Market size, 2025$1.77 Bn placeholder estimate
Forecast, 2034$3.09 Bn placeholder estimate
Growth (CAGR), 2025–20346.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, gender and end user (see all)
Key playersMerck & Co., Inc., GSK PLC, Serum Institute of India, Xiamen Innovax, Walvax Biotechnology (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials7 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe HPV Vaccines Market Analysis Executive Summary

HPV vaccines protect against human papillomavirus types that cause cervical and other cancers and genital warts.

Key segments of the HPV Vaccines market include type (9-Valent, Bivalent and Quadrivalent) and gender (Female and Male).

Bar chart: Europe HPV Vaccines market size, 2024–2034, placeholder estimates. $1.66 Bn in 2024, $1.77 Bn in 2025 and $3.09 Bn in 2034, 6.4% CAGR.
Europe HPV Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe HPV Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the HPV Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the HPV Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the HPV Vaccines market.

Competitive Landscape for HPV Vaccines Market in Europe

The HPV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for HPV Vaccines Market in Europe

HPV Vaccines in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6] and MHRA (UK)⁠[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[8] ClinicalTrials.gov lists 7 studies on HPV Vaccines that are recruiting, active or about to start in Europe.⁠[9]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] European Commission, health technology assessment. Checked 14 Nov 2026.

[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for HPV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in HPV Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

HPV Vaccines in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the HPV Vaccines market in Europe?
Placeholder estimate: about $1.77 Bn in 2025, rising to about $3.09 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the HPV Vaccines market in Europe growing?
Placeholder estimate: about 6.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the HPV Vaccines market report cover?
The report splits the market by type (9-Valent, Bivalent, Quadrivalent), gender (Female, Male) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the HPV Vaccines market?
Key players include Merck & Co., Inc., GSK PLC, Serum Institute of India, Xiamen Innovax and Walvax Biotechnology.
What is driving the HPV Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the HPV Vaccines market.
Who regulates HPV Vaccines in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on HPV Vaccines are running in Europe?
7 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on HPV Vaccines?
PubMed lists 1,087 papers on HPV Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on vaccines and women's health

See the topic